WAVE Life Sciences (NASDAQ:WVE) Stock Lifted to “Strong-Buy” by UBS Group

Posted by Stanley Muller on Oct 17th, 2026

UBS Group upgraded shares of WAVE Life Sciences (NASDAQ:WVE – Free Report) to a strong-buy rating in a research report report published on Wednesday,Zacks reports.

Several other equities analysts also recently commented on WVE. Wall Street Zen downgraded shares of WAVE Life Sciences from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 1st. William Blair started coverage on shares of WAVE Life Sciences in a research note on Friday. They issued an “outperform” rating for the company. Wedbush set a $13.00 price objective on shares of WAVE Life Sciences in a report on Friday, October 2nd. HC Wainwright restated a “buy” rating on shares of WAVE Life Sciences in a research report on Friday, October 2nd. Finally, B. Riley Financial decreased their target price on shares of WAVE Life Sciences from $31.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $21.53.

Check Out Our Latest Research Report on WAVE Life Sciences

WAVE Life Sciences Stock Performance

NASDAQ:WVE traded down $0.06 during mid-day trading on Wednesday, hitting $3.13. 3,281,728 shares of the stock were exchanged, compared to its average volume of 3,360,070. The firm’s 50-day simple moving average is $4.44 and its 200 day simple moving average is $5.73. The stock has a market capitalization of $617.33 million, a price-to-earnings ratio of -2.87 and a beta of -1.43. WAVE Life Sciences has a fifty-two week low of $3.04 and a fifty-two week high of $21.73.

WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). The firm had revenue of $2.27 million during the quarter, compared to analyst estimates of $7.45 million. WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. On average, analysts predict that WAVE Life Sciences will post -1.12 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Adrian Rawcliffe sold 12,700 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total value of $67,183.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Heidi L. Wagner sold 7,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total value of $42,070.00. Following the completion of the transaction, the director directly owned 44,930 shares of the company’s stock, valued at approximately $270,029.30. This trade represents a 13.48% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 23,564 shares of company stock valued at $132,476. Corporate insiders own 24.30% of the company’s stock.

Institutional Investors Weigh In On WAVE Life Sciences

A number of large investors have recently bought and sold shares of WVE. Readystate Asset Management LP bought a new position in WAVE Life Sciences in the 2nd quarter valued at about $27,465,000. Squarepoint Ops LLC lifted its holdings in shares of WAVE Life Sciences by 68.0% during the 2nd quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company’s stock worth $14,766,000 after acquiring an additional 1,029,052 shares during the period. Renaissance Technologies LLC boosted its position in shares of WAVE Life Sciences by 152.6% during the 1st quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock worth $4,330,000 after acquiring an additional 360,800 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in shares of WAVE Life Sciences by 42.6% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,149,127 shares of the company’s stock worth $8,202,000 after acquiring an additional 343,226 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of WAVE Life Sciences during the 1st quarter worth approximately $1,138,000. 89.73% of the stock is currently owned by institutional investors and hedge funds.

About WAVE Life Sciences

(Get Free Report)

WAVE Life Sciences Ltd. is a clinical-stage biotechnology company developing RNA medicines for genetic and other serious diseases. The company uses its proprietary oligonucleotide and RNA-editing technologies to target disease-causing genetic instructions, with the goal of selectively correcting, reducing, or modifying RNA activity.

Its development programs have included investigational therapies for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease.